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A. Athauda et al. / European Journal of Cancer 137 (2020) 45e5646(OS) (HR: 0.78; p < 0.001) and disease-specific survival (DSS) (HR: 0.78; p < 0.001) was
observed in females compared with males. No significant differences in OS (HR: 1.11;
p Z 0.045) or DSS (HR: 1.01; p Z 0.821) were observed in older patients compared with
younger patients.
For patients who underwent resection, older patients (15% vs 10%; p Z 0.03) and female
patients (14% vs 10%, pZ 0.10) were more likely to achieve favourable Mandard TRG scores.
Females experienced significantly more grade III nausea (10% vs 5%; p0.001), vomiting
(10% vs 4%; p0.001) and diarrhoea (9% vs 4%; p0.001) than males.
Conclusions: In this large pooled analysis using prospective randomised trial data, females had
significantly improved survival while experiencing more gastrointestinal toxicities. Older pa-
tients achieved comparable survival to younger patients and thus, dependent on fitness, should
be offered the same treatment paradigm.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
When combined, cancers of the oesophagus, oesopha-
gogastric junction (OGJ) and stomach (oesophagogas-
tric [OG] cancers) represent the second leading cause of
cancer-related mortality worldwide [1]. For patients in
Western populations with localised disease amenable to
surgical resection, combination chemotherapy in a
neoadjuvant or perioperative approach is commonly
used with modest improvements in overall survival (OS)
compared with surgery alone but with the cost of
increased toxicity [2,3]. Responses to chemotherapy and
clinical outcomes remain variable with approximately
half of patients who undergo resection subsequently
developing disease relapse, even with modern surgical
technique [4].
The effect of sexual disparity on cancer incidence,
aetiology and treatment has been relatively overlooked
until recently but may be a key component of a precision
medicine approach. Large epidemiological studies have
demonstrated that sexual differences exist in cancer
susceptibility and outcome with males having a higher
incidence and poorer outcomes of several tumour types
including OG cancer [1,5]. Whilst some of the differ-
ences in cancer incidence may be due to behavioural
factors such as smoking and/or hormonal influences [6]
(oestrogens are thought to have a protective effect in
terms of the development of some cancers), it has also
been suggested that differential sex-based gene expres-
sion signatures [7] and differing immune responses [8]
may be important. Sexual disparity also affects the
pharmacokinetic handling of cytotoxic chemotherapy
drugs through differences in body composition [9], drug-
metabolising enzyme expression [10], and drug-
erythrocyte binding [11] with the data suggesting that
higher dose intensities may be achieved in females
compared to males.
In addition to sexual disparity observed in cancer
incidence and outcome, age disparity also exists. OG
cancers are predominantly a disease of older age withmore than half of new cancers each year being diag-
nosed in people aged older than 75 years in the United
Kingdom (UK) [12,13]. However, there is usually
discrepancy in the use of treatment options compared
with younger patients and outcomes are generally
poorer for older patients [14,15]. The attribution of ef-
fects is complicated however by the increased impact of
comorbidities in the elderly population, making it diffi-
cult to ascertain the reason for poorer outcomes in this
patient group outside of clinical trials. Similar to the
differences in drug handling observed between males
and females, pharmacokinetic factors such as changes in
body composition, reduced hepatic capacity and
reduced renal perfusion [16] can also vary with
increasing age, regardless of comorbidities, and may
influence drug distribution, metabolism and clearance.
The lack of older participants in clinical trials limits not
only our knowledge about the pharmacokinetic
handling of cytotoxic chemotherapy drugs in older
patients but also the interpretation of clinical trial re-
sults into clinical practice.
Using four prospective randomised controlled trials
(RCTs) evaluating the use of neoadjuvant or perioper-
ative chemotherapy in operable OG cancer, we investi-
gated the effect of sex and age on treatment outcomes.2. Materials and methods
2.1. Methods
2.1.1. Patient cohorts
Individual patient data from four prospective RCTs
evaluating neoadjuvant/perioperative chemotherapy for
potentially operable OG cancer were included in this
analysis: OE02, Medical Research Council Adjuvant
Gastric Infusional Chemotherapy (MAGIC) trial
(ISRCTN 93793971), OE05 (ISRCTN 01852072) and
ST03 (ISRCTN 46020948). Individual trial design and
results have previously been published, but in short:
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localised oesophageal cancer who were randomly allo-
cated to receive two cycles of cisplatin and fluorouracil
(CF[5-FU]) chemotherapy followed by surgery or sur-
gery alone [2]; MAGIC investigated the use of periop-
erative chemotherapy (three cycles of epirubicin,
cisplatin, 5-FU [ECF] pre- and post-operatively)
compared with surgery alone in 503 patients with
potentially resectable adenocarcinoma of the stomach,
OGJ or lower oesophagus between 1994 and 2002 [3];
OE05 recruited 897 patients with operable oesophageal
adenocarcinoma between 2005 and 2011 and rando-
mised between two cycles of CF or four cycles of epi-
rubicin, cisplatin, capecitabine (ECX) chemotherapy
given pre-operatively [17]; ST03 investigated the addi-
tion of the antiangiogenic monoclonal antibody bev-
acizumab to perioperative ECX chemotherapy in 1063
patients with OG adenocarcinoma recruited between
2007 and 2014 [4]. Based on the lack of improved effi-
cacy with bevacizumab, patients who received this drug
were also pooled in this analysis.
All four trials were designed and managed by the
Medical Research Council Clinical Trials Unit at Uni-
versity College London and assessed a similar patient
population. These particular trials were chosen as they
represent the largest randomised trials conducted in this
patient population in the UK, and the clinical and
pathological data were readily available to our group.
The majority of patients were recruited from UK centres
with MAGIC and OE02 including a small number of
patients from other countries, which amount to less than
1% of the total population. There were no upper age
limit restrictions in any trial and none included planned
dose changes based on the age of patients.
2.1.2. Analysis of toxicity and tumour regression grade
Individual patient data were available from all four
trials. Baseline patient demographic data common to all
trials were age, sex and World Health Organisation
(WHO) performance status. In addition, OE05 and
ST03 included data on baseline tumour stage. In the
OE02 trial, toxicity information was not recorded.
MAGIC, OE05 and ST03 all recorded toxicity infor-
mation on nausea, vomiting, diarrhoea and stomatitis in
accordance with the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3.0. In
addition, OE05 and ST03 both collected data on
tinnitus, thrombocytopaenia, neutropenia, cardiac
toxicity, loss of taste, infection (neutropenic), peripheral
neuropathy, palmar-plantar erythrodysesthesia (PPE),
renal toxicity, deep vein thrombosis (DVT) and pul-
monary embolism.
Tumour regression grade (TRG) was assessed in
accordance with the Mandard system [18] as follows:
TRG 1 (complete regression/fibrosis with no evidence of
tumour cells), TRG 2 (fibrosis with scattered tumour
cells), TRG 3 (fibrosis and tumour cells with adominance of fibrosis), TRG 4 (fibrosis and tumour cells
with a dominance of tumour cells), and TRG 5 (tumour
without evidence of regression). For all trials, central
TRG review was available and was assessed by two in-
dependent experienced pathologists and a third if no
consensus was agreed. Further disagreements were
settled by a majority call. Central TRG data were
available for 1799 (83%) of the 2165 patients who un-
derwent surgical resection after neoadjuvant
chemotherapy.
2.1.3. Statistical analysis
The primary outcome measure for this analysis was OS,
and secondary outcome measures were disease-specific
survival (DSS), Mandard TRG and incidence of grade
III toxicity. Data were analysed using a two-stage
approach: first analysing data within trials and then
combining the data across trials using a fixed-effects
meta-analysis. To assess the impact of model choice on
results, sensitivity analyses were also performed using a
random-effects meta-analysis.
For the purposes of analysis, age was dichotomised
into patients aged <70 years and patients 70 years.
The decision to dichotomise age was driven by the fact
that patients aged 70 years and older are often treated
differently in the clinical setting, especially in the UK.
The intent of the age analyses was predominantly to
challenge/confirm this clinical approach.
OS was defined as the time from randomisation until
death from any cause, with surviving patients censored
at their date of last follow-up. DSS was defined as the
time from randomisation to death from cancer, with
surviving patients censored at their date of last follow-
up, and patients dying of other causes censored at their
date of death. Survival analyses were performed for all
trial participants in the intention-to-treat population.
Mandard TRG was categorised into responders (grade I
or II) and non-responders (grade IIIeV) and was only
analysed for patients who were randomised to a pre-
operative chemotherapy treatment arm and subse-
quently underwent surgical resection. Toxicity analysis
was only performed in patients who received at least one
cycle of neoadjuvant chemotherapy in the MAGIC,
OE05 and ST03 trials, as toxicity data were not collected
in OE02.
Time to event outcome measures (OS and DSS) were
analysed using a Cox model to obtain hazard ratios
(HRs) for the effect of age and sex. Binary outcome
measures (Mandard TRG and toxicity) were analysed
using logistic regression models to obtain odds ratios.
All models were adjusted for WHO performance status
and the type of chemotherapy received (none, CF, ECF/
ECX, ECXþbevacizumab). A further analysis of OS
was performed to also adjust for baseline tumour stage
(stage I and II vs stage III and IV, in accordance with
Union for International Cancer Control TNM 6th edi-
tion) in patients recruited to OE05 and ST03 alone.
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each study and the number of participants included in
each analysis. To account for multiple testing, a P-value
of <0.01 is taken to indicate statistical significance. No
imputation of missing data was performed.
3. Results
3.1. Demographics
3265 patients were included; 2668 (82%) males and 597
(18%) females. Of all patients, 2627 (80%) patients were
aged <70 years and 638 (20%) were aged 70 years.
There was no significant difference in age range between
males and females. 2234 (68%) of patients were of WHO
performance status 0, 1008 (31%) were WHO 1, and 23
(1%) were WHO >1 (all recruited through OE02). 1861
(71%) of patients aged <70 years and 373 (58%) of pa-
tients aged 70 years had a performance status of 0. In
addition, 1824 (68%) of males and 410 (69%) of females
had a performance status of 0. Owing to the nature of
the individual studies, some included predominantly
oesophageal cancers and others predominantly gastric
or OGJ cancers. However, once the studies were pooled
the proportions of patients with oesophageal, OGJ or
gastric cancer were relatively balanced across the whole
group. The vast majority of patients had adenocarci-
nomas (92%) with the exception of 268 patients in OE02
who had squamous cell or undifferentiated carcinomas,
but this represents only 8% of the total patients in this
analysis. Baseline characteristics of included partici-
pants from each trial are shown in Table 1 and numbers
of participants in each age/sex subgroup according toFig. 1. Included trials and parbaseline characteristics and chemotherapy outcome are
shown in Table 2.
3.2. Toxicity and chemotherapy completion
Based on toxicities captured commonly across trials
(Table 3), older patients experienced more grade III
neutropaenia (30% vs 22%; P Z 0.004) than younger
patients. Females experienced significantly more grade
III nausea (10% vs 5%; PZ<0.001), vomiting (10% vs
4%; PZ<0.001) and diarrhoea (9% vs 4%; P < 0.001)
than males. No significant differences were seen in the
occurrence of grade III tinnitus, thrombocytopaenia,
cardiac toxicity, loss of taste, infection/febrile neu-
tropaenia, peripheral neuropathy, PPE, renal toxicity,
DVT and pulmonary embolism.
Of the whole study population who were allocated to
receive chemotherapy, 2246 patients (86%) completed
the planned number of neoadjuvant chemotherapy cy-
cles. A higher proportion of younger patients (87% vs
80%; P < 0.001) and males (87% vs 81%; P Z 0.001)
completed the planned number of chemotherapy cycles
compared with older patients and females respectively.
3.3. Pathological treatment response (Mandard TRG)
There was no difference in the number of patients who
underwent surgical resection between younger and older
patients (84% vs 81%; P Z 0.03), as well as between
females and males (86% vs 83%; P Z 0.07). For those
patients who underwent surgical resection after neo-
adjuvant chemotherapy, older patients achieved similar
rates of favourable Mandard TRG 1 and 2 scores asticipants for each analysis.
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achieved similar rates of Mandard TRG 1 and 2 scores
compared with males (14% vs 10%, P Z 0.099).
3.4. Survival
A significant improvement in OS (28.6 vs 23.7 months,
HR: 0.78 (0.70e0.88); P < 0.001) and DSS (35.3 vs 27.2
months, HR: 0.78 (0.69e0.88); P < 0.001) was observed
in females versus males (Figs. 2 and 3). OS was similar
between younger and older patients (24.5 vs 22.3
months, HR: 1.11 (1.00e1.24); P Z 0.05) as was DSS
(28.0 vs 28.0 months, HR: 1.01 (0.90e1.14); P Z 0.82)
(Figs. 4 and 5).
After adjusting for baseline stage in patients recruited
through OE05 and ST03 only, female patients still had
significantly improved OS (HR: 0.76 [0.63e0.91];Table 1
Baseline patient and tumour characteristics for each trial.
Characteristic Trial
OE02 N Z 802 OE05 N Z 897
No. (%) No. (%)
Sex
Male 603 (75) 810 (90)
Female 199 (25) 87 (10)





<70 637 (79) 747 (83)
70 165 (21) 150 (17)
Total 802 (100) 897 (100)
WHO performance status
0 532 (66) 603 (67)
1 247 (31) 294 (33)
2 21 (3) 0 (0)
Total 802 (100) 897 (100)
cT-stage















Adenocarcinoma 533 (66) 897 (100)
Squamous 247 (31) 0 (0)
Total 780 (97) 897 (100)
OGJ, oesophagogastric junction; MAGIC, Medical Research Council Ad
nisation; c, clinical stage.P Z 0.004) and DSS (HR 0.75 [0.62e0.90]; P Z 0.002)
compared with male patients. In regards to age, no
significant difference was seen in respect to OS (HR:
1.07 [0.91e1.25]; P Z 0.43) or DSS (HR 0.99
[0.84e1.16]; P Z 0.87).
In a separate analysis of the effect of sex on survival
in the control arms of OE02 and MAGIC (i.e. in pa-
tients who underwent immediate surgical resection
without any neoadjuvant chemotherapy; N Z 655), fe-
males still demonstrated improved OS compared to
males and this approached but did not meet statistical
significance (HR: 0.83 [0.68e1.02]; P Z 0.07).
All outcomes by sex and age analysis are summarised
in Supplementary Table 1. No analysis showed evidence
of significant heterogeneity of effect between trials. To
assess the impact of model choice on the results, sensi-
tivity analyses were performed using a random-effectsMAGIC N Z 503 ST03 N Z 1063 Total N Z 3265
No. (%) No. (%) No. (%)
396 (79) 859 (81) 2668 (82)
107 (21) 204 (19) 597 (18)




398 (79) 845 (79) 2627 (80)
105 (21) 218 (21) 638 (20)
503 (100) 1063 (100) 3265 (100)
342 (68) 757 (71) 2234 (68)
161 (32) 306 (29) 1008 (31)
0 (0) 0 (0) 21 (1)
503 (100) 1063 (100) 3265 (100)
Data not available 6 (1) 14 (0)
126 (12) 213 (6)
785 (74) 1560 (48)
58 (5) 85 (3)
975 (92) 1872 (57)
Data not available 217 (20) 411 (13)
748 (70) 1443 (44)
965 (91) 1854 (57)
73 (15) 144 (14) 937 (29)
58 (12) 536 (50) 676 (21)
372 (74) 383 (36) 755 (23)
503 (100) 1063 (100) 2368 (73)
503 (100) 1063 (100) 2996 (92)
0 (0) 0 (0) 247 (8)
503 (100) 1063 (100) 3243 (99)
juvant Gastric Infusional Chemotherapy; WHO, World Health Orga-
Table 2
Patient characteristics and outcomes by age and sex subgroups.
Characteristic/outcome <70 70 Total N (%)
Male N (%) Female N (%) Male N (%) Female N (%)
Trial OE02 490 (61) 147 (18) 113 (14) 52 (6) 802
MAGIC 307 (61) 91 (18) 89 (18) 16 (3) 503
OE05 675 (75) 72 (8) 135 (15) 15 (2) 897
ST03 682 (64) 163 (15) 177 (17) 41 (4) 1063
Total 2154 (66) 473 (14) 514 (16) 124 (4) 3265 (100)
WHO PS 0 1521 (71) 340 (72) 303 (59) 70 (56) 2234 (68)
1 633 (29) 133 (28) 211 (41) 54 (44) 1031 (32)
Total 2153 473 514 124 3265 (100)
cT-stage 1 9 (1) 2 (1) 3 (1) 0 (0) 14 (1)
2 147 (11) 28 (13) 34 (12) 4 (8) 213 (11)
3 1103 (84) 176 (83) 240 (81) 41 (84) 1560 (83)
4 56 (4) 7 (3) 18 (6) 4 (8) 85 (5)
Total 1315 213 295 49 1872 (100)
cN-stage N0 279 (21) 51 (24) 71 (24) 10 (20) 411 (22)
N1þ 1024 (79) 160 (76) 220 (76) 39 (80) 1443 (78)
Total 1303 211 291 49 1854 (100)
Tumour location Oesophageal 593 (40) 161 (40) 130 (34) 53 (49) 937 (40)
OGJ 481 (33) 75 (19) 105 (28) 15 (14) 676 (29)
Gastric 405 (27) 165 (41) 144 (38) 41 (38) 755 (32)
Total 1479 401 379 109 2368 (100)
Histology Adenocarcinoma 2027 (95) 381 (81) 496 (97) 92 (75) 2996 (92)
Squamous 114 (5) 88 (19) 14 (3) 31 (25) 247 (8)
Total 2141 469 510 123 3243 (100)
Completed planned chemotherapy No 209 (12) 56 (16) 72 (17) 27 (31) 364 (14)
Yes 1553 (88) 287 (84) 346 (83) 60 (69) 2246 (86)
Total 1762 343 418 87 2609 (100)
Underwent resection No 341 (16) 61 (13) 99 (20) 20 (17) 521 (16)
Yes 1786 (84) 402 (87) 402 (80) 100 (83) 2690 (84)
Total 2127 463 501 120 3211 (100)
TRG response 1e2 112 (9) 34 (14) 39 (15) 8 (14) 193 (11)
3e5 1121 (91) 210 (86) 226 (85) 49 (86) 1602 (89)
Total 1233 244 265 57 1799 (100)
TRG, tumour regression grade; OGJ, oesophagogastric junction; MAGIC, Medical Research Council Adjuvant Gastric Infusional Chemotherapy;
WHO, World Health Organisation; c, clinical stage at baseline.
Table 3


































































































MAGIC, Medical Research Council Adjuvant Gastric Infusional
Chemotherapy.
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effect of age on neutropaenia rates, all random-effects
meta-analyses produced similar results to the fixed-ef-
fects models. For neutropaenia, the p-value for the effect
of age was 0.004 for the fixed-effects analysis but 0.014
from the random-effects model. Our pre-defined cut-off
for statistical significance was 0.01; therefore some
caution is recommended when interpreting this result.4. Discussion
This study, using patient-level data collected from four
large prospective RCTs, represents the largest pooled
analysis of the effects of age and sex on toxicity of
neoadjuvant chemotherapy and survival in operable OG
cancer. Females had statistically significant improved
survival, both in terms of OS and DSS, compared to
males including after adjustment for baseline stage. The
survival difference between males and females in our
study remained apparent, albeit less pronounced, when
the control arms of OE02 and MAGIC (i.e. patients
who underwent surgery without any neoadjuvant
Fig. 2. Kaplan-Meier curves of overall survival (OS) and disease-specific survival (DSS) by sex.
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approached but did not reach statistical significance.
This result demonstrates that the prognostic effect of
surgery is more pronounced in the study population
who received neoadjuvant chemotherapy, suggesting a
predictive effect from exposure to chemotherapy. The
survival of patients aged 70 years and older was com-
parable to patients aged less than 70 years.Worldwide, females have a longer life expectancy
than males and this trend has more recently been
demonstrated in cancer survival too [5,19]. The large
population-based EUROCARE-4 data set demon-
strated that female sex was an independent predictor of
survival in oesophageal and gastric cancer, as well as in
a number of other cancers [20] and analysis of the Sur-
veillance, Epidemiology and End Results database has
Fig. 3. Forest plots of DSS (left) and OS (right) benefit in females vs males. OS, overall survival; DSS, disease-specific survival.
Fig. 4. Kaplan-Meier curves of overall survival (OS) and disease-specific survival (DSS) by age.
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Fig. 5. Forest plots of DSS (left) and OS (right) in older vs younger patients. OS, overall survival; DSS, disease-specific survival.
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survival benefit for females has also been observed in
lung adenocarcinoma [22], although the converse has
been observed in bladder cancer [23]. There remains
limited data on the influence of sex on survival in
operable OG cancer; a longer metastasis-free survival
time for females undergoing pre-operative chemo-
radiation has been demonstrated; however, the number
of participants in this study was small and females
presented with earlier stage disease than males [24].
The molecular basis for differential cancer survival
between males and females remains incompletely un-
derstood but is likely to be secondary to both inherent
biological differences between the sexes, as well as
tumour-specific molecular changes. Sex is one variable
that influences both innate and adaptive immune re-
sponses which can hugely affect both pathogenesis, as
well as prognosis from non-sex-specific cancers. Multi-
ple putative mediators of immunity such as sex hor-
mones, sex chromosomeelinked genetic changes,
metabolic and bacterial mediators, reproductive stage
and environmental factors are thought to be differen-
tially expressed in males and females at different stages
of development and subsequently may influence the
immune system in varying ways throughout the course
of life [8]. Our increasing understanding of the complex
interplay between immune cells and cancer cells, as well
as the corresponding effect on tumourigenesis, thera-
peutic response and prognosis indicates that sex-specific
immunological changes may contribute significantly to
survival differences between males and females.
In regards to tumour-specific differences, Yuan et al.
[7] analysed thirteen cancers of The Cancer Genome
Atlas and identified a group of cancers with sex-biased
gene expression signatures with 53% of clinically
actionable genes. The majority of cancers in this group
demonstrate sex-differential incidence and mortality,
highlighting the significant impact that molecular-level
understanding of the sex-effect can have on drug
development, as well as clinical practice. The tumour-
associated stroma may also play a key role in the
disparity between tumours of males and females, for
example, differences in expression of androgen and
oestrogen receptors in the stroma of male and female
patients with gastric cancer, and their correlation with
tumour stage has recently been demonstrated [25].
Altogether, it is likely that a highly complex interplaybetween biological and environmental factors influences
the improved cancer-specific survival for females which
has been demonstrated in this and other studies, and the
exact underlying mechanisms require further
consideration.
In addition to the observed survival differences,
toxicity rates and number of completed chemotherapy
cycles also varied between males and females in our
study. The occurrence of higher rates of toxicity in fe-
males has previously been reported for a number of
different cytotoxic drugs and relates to both haemato-
logical and non-haematological toxicities [22,26,27].
Although the increased susceptibility of toxicities such
as nausea and alopecia may be influenced by differing
perceptions between females and males, differences in
the occurrence of objective haematological parameters
supports the notion of sex-specific variation in drug
exposure and sensitivity. Within our analysis, the rate of
severe gastrointestinal (GI)-specific toxicities was
significantly increased in females although haemato-
logical parameters of toxicity, such as neutropaenia and
thrombocytopaenia, were not. Recent results from a
pooled analysis of 1654 patients with advanced OG
cancer have also shown that females experienced more
GI-specific toxicities than males when treated with
equivalent first-line chemotherapy, although no signifi-
cant survival differences were seen [27]. In both analyses,
females completed fewer cycles of planned chemo-
therapy than males, suggesting that increased toxicity
may impact on the effective administration of
chemotherapy.
Despite the observed reduction in dose intensity for
females and older patients in our analysis, both groups
achieved similar rates of favourable regression as males
and younger patients, suggesting that physiological
differences contributing to sex and age-specific exposure
to chemotherapy is adequate to induce comparable
tumour responses despite a reduced overall dose. Pre-
vious studies support this theory by demonstrating a
correlation between higher rates of toxicity, increased
response rates and improved survival in females [28,29].
Independent of sex, a number of systemic anti-cancer
therapies also display a toxicity-response relationship,
whereby higher rates of toxicity are associated with
better responses to therapy, an example of which is the
skin rash associated with cetuximab [30]. As the
maximum tolerated doses of cytotoxic drugs have
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studies which have a male preponderance, it may be that
female patients are being treated with doses above those
which will be efficacious but at the cost of increased
toxicity. This supports the notion that effective dosage
of systemic anti-cancer therapies should be determined
on an individualised basis taking into account physio-
logical and pharmacokinetic differences between pa-
tients of different sex and age.
A step forward in the personalisation of cytotoxic
chemotherapy administration is through the incorpora-
tion of DPYD-genotype testing in patients planned to
receive fluoropyrimidines. There is mounting evidence
that the routine use of DPYD testing to guide dose
adjustments in clinical practice and within clinical trials
is feasible and of great benefit [31], and this practice has
been adopted in many UK institutions. In addition, the
routine use of UGT1A1 polymorphism testing occurs in
many institutions to guide irinotecan dosing. The uti-
lisation of therapeutic drug monitoring (TDM) of
cytotoxic drugs, many of which have narrow therapeutic
indices but highly variable pharmacokinetics, would be
greatly informative for a personalised approach. How-
ever, the use of TDM is not commonplace in oncology
owing to a number of issues including the use of com-
bination chemotherapy regimens which make it difficult
to establish therapeutic ranges for individual drugs,
paucity of published data and analytical challenges with
prodrugs to name a few [32]. There should be a
continued effort to promote TDM guidelines in
oncology practice and through clinical trials to evaluate
the benefits of individualised chemotherapy.
Sexual disparity in cancer treatment efficacy can also
be seen beyond traditional cytotoxic chemotherapy
drugs. It has been shown that immune checkpoint in-
hibitors (ICIs) tend to be more effective in males than
females [33,34], whereas ICIs combined with chemo-
therapy tends to be more effective in females [35]. This
differential response to immune-modulating drugs is not
entirely surprising, given the significant physiological
differences which exist between male and female im-
mune systems as described previously. Consequently,
female tumours are considered by some to be ‘immune
hot’ but display low tumour antigenicity, whereas male
tumours are considered ‘immune cold’ but display high
tumour antigenicity. In addition, it has been observed
that females have a higher chance of exhibiting immune-
mediated adverse events than males [36]. Taken
together, it is becoming increasingly clear that immu-
notherapeutic strategies, in addition to systemic
chemotherapy, may benefit from being tailored to the
patient’s sex.
As the majority of OG cancers in high- and middle-
income countries are diagnosed in patients aged 70 years
and older, it is now recognised that these cancers are
predominantly a disease of older people. However, this
population is under-represented in the trials included inthis analysis, for example, only 3% of the OE05 partic-
ipants were aged >75 years despite more than half of
cancers being diagnosed in this age group in the UK.
Owing to stringent trial eligibility criteria, almost all
patients included in this analysis had a performance
status of 0 or 1 and therefore represent a fit older pop-
ulation, hence these results may not be generalisable to
all patients with OG cancer in the clinic. Nevertheless,
these results are clinically important as they provide
reassurance to clinicians and surgeons that fit older
patients can be managed safely with the same curative
treatment paradigm as younger patients and achieve
comparable survival rates. These results are in keeping
with a previous retrospective series, demonstrating
comparable survival outcomes in patients aged 70
years treated with neoadjuvant chemotherapy and sur-
gery in Germany [37]. A randomised phase II study
conducted by the same group in patients aged 65 years
showed that triplet chemotherapy was feasible in older
patients with locally advanced or metastatic OG cancer
but with the cost of increased toxicity and detriment on
quality of life [38]. For palliative chemotherapy in
advanced disease, tumour control and symptomatic
improvement are more important driving factors for
treatment, and clinical trials have now been designed to
assess different regimens and dosages of drugs in older
patients who may be frailer but still candidates for sys-
temic therapy. The recently reported phase III GO2
study [39] demonstrated that reduced dose chemo-
therapy can achieve comparable survival to higher doses
without compromising quality of life in frail older pa-
tients with advanced OG cancer. Based on our present
study however, age alone should not be a discriminatory
factor in determining chemotherapy regimen or dosage
in patients with operable OG cancer.
A limitation of our study is the lack of uniform
collection of baseline data, especially from the older
studies (OE02 and MAGIC), which makes direct com-
parison of certain variables challenging. There is also a
lack of information on potentially important con-
founding variables such as histopathological subclassi-
fication, baseline site of tumour and comorbidity index.
In addition, although we have pointed towards a num-
ber of potential contributory factors accounting for
survival differences between males and females based on
available literature, information on these factors was not
collected during the running of the included trials. This
present study suggests more effort should be put into
assessing these factors in future clinical trials. However,
the large number of patients included in this analysis
and the prospective collection of robust patient data
through relatively uniform large clinical trials allows
strong comparisons to be made, and this is a great
strength. The use of individual patient-level data rather
than aggregate data is also a strength of our study. The
fact that our analysis includes significant numbers of
patients in each subgroup of tumour site (lower
A. Athauda et al. / European Journal of Cancer 137 (2020) 45e56 55oesophageal, OGJ and gastric) enables these results to
be relevant to all patients with OG cancer, which is
important as current management regimens do not
differentiate between these sites.
5. Conclusion
These results, drawn from four robust clinical trial data
sets, suggest that sex as a readily available, cost-free,
biological variable should be strongly considered in the
stratification and interpretation of clinical trials as an
independent regulator of chemotherapy efficacy and
survival. The findings of this study suggest that clini-
cians should be aware of the differing toxicities and
dose-response variability experienced by males and fe-
males as well as older and younger patients to provide
education, tailor supportive measures, and improve
tolerability of treatment for individual patients. Inherent
sex-specific physiological differences are likely to ac-
count for the survival differences observed in this anal-
ysis however molecular characteristics of the tumour
and stroma may also play a causative role. Further
research is needed to ascertain any molecular changes
which are potentially driving such differences in tu-
mours between patients of differing sex.
Although males and females may both potentially
benefit from sex-specific treatment strategies in operable
OG cancer, age should not be a discriminatory factor
and older patients, depending on fitness, should be
treated with the same paradigm as younger patients.
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